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Abstract
Cervical-level injuries account for the majority of presented spinal cord injuries (SCIs), yet there
are few therapies that successfully improve the overall quality of life for patients. Regenerative
therapies aimed at ameliorating deficits in respiratory and motor function are urgently needed.
Cellular transplantation strategies are a promising therapeutic avenue. These strategies seek to
overcome the inhibitory environment of the injury site, increase native regenerative capacities,
provide scaffolding to bridge the lesion, or replace injury-lost neurons and glia.
Numerous considerations must be taken into account, however, when designing effective cellular
transplantation therapies, most notably of which is cell source. Each cell source offers its own
unique  attributes—both  positive  and  negative—that  directly  correspond  with  functional
outcomes and clinical translation. Here we discuss three different cell types currently used in
cellular  transplantation  strategies  to  treat  cervical  SCIs:  mesenchymal  stem  cells  (MSCs),
embryonic stem cells (ESCs),  and induced pluripotent stem cells (iPSCs).  By illustrating the
characteristics of each cell type and outlining the studies and clinical trials in which they have
been featured,  we hope to  provide  the  reader  with  a  detailed  understanding of  both  their
capabilities and also their potential drawbacks in experimental and clinical settings.
Keywords: cervical spinal cord injury, stem cell therapies, cellular transplantation,
functional outcomes, regenerative strategies
1. Introduction
1.1. The impact of cervical SCI
Spinal cord injuries (SCIs) create a formidable encumbrance on the US healthcare service with
over half of all injuries occurring at the cervical level. While most causes of SCI can be attributed
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
to accidents or violence, the incidence of cervical-specific injuries continues to rise from
particularly distinctive causes [1,2]. This is in part due to the ever-increasing spectrum of injury
types, such as those sustained in direct military environments or as a result of changes in
tactical armor design [3–6]. Others include improvements in emergency medicine leading to
better survival rates [7], the growth of the aging population as a result of advances in
preventative care [8–10], and lifestyle choices leading to structural degradation of the cervical
spine [11,12].
Survivors of cervical SCI are faced with dramatic life changes owing to lengthy and repeat‐
ed hospitalizations and the need for full- or part-time caretakers, overall resulting in a loss of
personal independence. Combined with a frequent inability to maintain employment or
contribute to the workforce, patients incur substantial financial expenses—over the course of
their lifetime, a 25-year-old SCI patient can expect to accrue up to $4.5 million in direct costs
alone. Overall, SCI costs the nation upward of $40.5 billion annually, as per a 2009 report by
the Christopher and Dana Reeve Foundation [1,2]. Although recent advances have resulted in
increased survival rates, quality of life still remains poor; patients encounter a gradation of
sensory deficits, respiratory deficits, motor dysfunction, and paralysis based on their specif‐
ic injury location. Therapies designed to ameliorate some of these complications, even
partially, are drastically needed and would make a radical impact in easing the financial,
emotional, and physical burden experienced by cervical SCI patients.
1.2. The pathophysiology of cervical SCI
The cervical spinal cord contains the long tracts connecting the rostral and caudal portions of
the central nervous system (CNS), as well as sensory and motor neurons. Cervical SCI in
mammals initiates large zones of necrosis at the site of injury, creating gaps in the circuitry
and preventing communication within the CNS. Axons within the spinal cord fail to regener‐
ate after injury and retract toward the soma from the lesion border. Overall this culminates in
crucial changes to normal upper limb function in mammals and disrupts motor function in
humans resulting in paralysis and diaphragm-mediated respiration [13].
SCI is characterized by two distinct phases: primary and secondary injuries. During primary
injury, the delicate spinal cord tissue is mechanically compromised due to shearing and
compression forces, either by direct contact or inadvertently through manipulation of the
vertebrae. This leads to mechanical injury, disruptions in vasculature and respiration,
neurogenic shock, inflammation, membrane compromise, and alterations in ion and neuro‐
transmitter levels [14–16]. While the primary injury phase leads to an immediate and often
serious impairment of neurological function, it is the secondary injury phase that typically
dictates the full magnitude of injury. There are approximately 25 established mechanisms to
date by which this occurs, but still much ambiguity as to how these pathways converge upon
each other to determine the full manifestation of injury [17,18]. Overall, this biochemical
cascade activates the ischemic pathway, inflammation and immune responses, swelling, and
neuronal apoptosis and leads to neurotransmitter imbalances that underlie excitotoxicity [19–
25].
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1.3. Regeneration and plasticity of the CNS
Prior evidence suggested that the adult mammalian CNS did not regenerate, predominantly
due to the unlikely event of axonal regeneration through the inhibitory milieu of the spinal
lesion [26]. However, some degree of functional recovery is often seen, possibly as a result of
reorganization of spared circuitry from innate axonal sprouting of spared and intact fibers [26–
28]. Experimental evidence has shown that this process can be influenced and axonal regen‐
eration encouraged via the use of other synergistic therapies. These include the addition of
neurotrophic growth factors [29–32], the deletion of inhibitory factors typically associated with
the lesion [33–35], and rehabilitation regimens and physical activity [36–38]. Despite this, the
innate regenerative capacities of the CNS are often overwhelmed by the extent of injury and
functional recovery is limited at best.
Given SCI’s multifactorial pathophysiology and the inherent complexity of the CNS, any
potentially successful treatment must be effective in positively addressing multiple deficits.
Cellular transplantation therapies offer an attractive means of accomplishing this by repopu‐
lating SCI-lost neurons and glia, increasing native regenerative capacities through trophic and
immunomodulatory factors secreted by transplanted cells, and providing scaffolding to bridge
the inhibitory milieu of the lesion site [20,29,30,32,39–43]. Furthermore, the potency of stem
cells makes them an ideal candidate by circumventing the impediments of harvesting and
transplanting adult neurons. By promoting neurite regeneration and replenishing appropri‐
ate cell populations, it may be possible to reconnect rostral and caudal neural circuitry and
restore function.
In recent decades, the therapeutic promise of cellular intraspinal transplantation has gained
significant interest and has eventuated in preliminary clinical trials. Numerous preclinical
experiments have been developed to target SCI using peripheral nerve bridges, Schwann cells,
Figure 1. A summary of the different stem cell types. Panel (A) shows the origin and isolation of the cells, (B) shows
their differentiation potential, and (C) describes transplantation methods used and their intended goals for treatment
of cervical SCI.
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olfactory glia, mesenchymal stem cells (MSCs), embryonic-derived stem cells, and induced
pluripotent stem cells (iPSCs). However, the vast majority of these do not address cervical-
level injury [44–52].
Here, we highlight the current literature on embryonic, mesenchymal, and induced pluripo‐
tent stem cell-based cellular transplantation with an emphasis on cervical-level SCI. We discuss
the benefits and disadvantages of each cellular source, and consider possible future therapeu‐
tic avenues. Figure 1 provides a summary of these cellular types and their origins, including
transplantation methods used and their intended goals for treatment of cervical SCI.
2. Mesenchymal stem cells (MSCs)
2.1. Isolation and purification of MSCs
Transplantation of mesenchymal stem cells (MSCs), also known as bone marrow stromal
cells (BMSCs) or mesenchymal progenitor cells, is a strategy currently being investigated to
ameliorate the array of deleterious effects following SCI. The terms mesenchymal stromal cells
and mesenchymal stem cells have been interchangeably used in the published literature;
however there are demonstrable differences between the cells. Mesenchymal stem cells are a
subset of stromal cells that maintain the same fibroblast morphology and specific marker
expression; however they also have the potential for self-renewal and to differentiate into
adipocytes, chondrocytes, and osteoblasts in vitro [53–55]. For cultured cells to be defined as
MSCs, they should demonstrate the following: (1) adherence to plastic under culture condi‐
tions, (2) expression of CD105, CD73, and CD90, (3) lack of expression of CD45, CD34, CD14/
CD11b, CD79/CD19, and HLA-DR surface markers, and (4) possession of the transdifferen‐
tiation potential to mesodermal lineages in vitro [56].
MSCs reside in a wide variety of tissues but are typically extracted from bone marrow and
adipose tissue and to a lesser extent the umbilical cord. Their wide distribution and perivas‐
cular origin [57] account for their capability to sense and respond to injury by secreting trophic
and anti-inflammatory factors [58,59]. The first report of MSCs isolation from bone marrow
was by Friedenstein and colleagues. [60]. The spindle-shaped cells isolated were defined as
colony-forming units (CFU) with the potential for in vitro culture for further transplantation
in vivo [61]. It was only in 1999 that Pittenger and colleagues established the multi-lineage
differentiation potential of MSCs into distinct mesodermal lineages [62]. Originally, Frieden‐
stein and colleagues cultured MSCs by plastic adherence. Since then, many groups have
modified this technique by expanding MSCs as a suspension culture [63–65].
Since its origin, bone marrow-derived MSC culture techniques have been continuously
validated and improved. While isolation via plastic adherence is effective, the isolation of such
cells does not yield a purified population of MSCs leading to varied growth kinetics and
differentiation capabilities [66]. The complications of a heterogeneous population can be
overcome by the purification of MSCs by using single specific surface markers such as Stro-1,
CD271, Stro-3, CD73, and CD2000 [65,67]. Transplantation of MSCs, selected as above,
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following SCI in a rat model translated to marked improvement in functional recovery and
increased tissue sparing [68].
Compared to iPSCs or embryonic stem cells (ESCs), MSCs overcome the ethical concerns of
isolation, as MSCs can be extracted from one’s own bone marrow or adipose tissue [69]. Recent
data has indicated the principal therapeutic advantages of MSCs are their neuroprotective
[70,71] and immunomodulatory [71,72] properties.
2.2. Regenerative potential of MSCs
The ubiquitous presence of MSCs around blood vessels makes them more amenable to respond
to cues from tissue damage. Recent reports attribute the immunomodulatory function of MSCs
as suitable for regenerative therapies and thereby tissue repair. Experimental evidence has
shown that the immunomodulatory effect of MSCs is possibly due to their ability to sup‐
press T-cell proliferation by secreting soluble factors such as TGF-beta and hepatocyte growth
factor and not via apoptosis [73]. MSCs can also exert their immunomodulatory effect by
shifting the balance in favor of regulatory T-cells, known suppressors of the immune system
that are triggered by anti-inflammatory cytokines such as IL10. Aggarwal and Pittenger [74]
co-cultured populations of immune cells with human MSCS and demonstrated that MSCs
altered the secretory cytokine profile, restored balance between helper T-cells and macro‐
phages, reduced pro-inflammatory cytokines, and increased anti-inflammatory molecules,
thus favoring the induction of a tolerant anti-inflammatory phenotype [74,75]. Shifting and
quenching the inflammatory response then redirects the body’s resources toward tissue repair
and growth [76,77]. Thus far, preclinical studies have demonstrated the potential for MSCs
and their secreted factors to repair damaged tissue through their immunomodulatory and
neuroprotective properties.
2.3. Treating cervical SCI with MSCs: toward clinical application
Clinically, the majority of interventions in treating SCI are pharmaceutically based and
designed primarily to manage pain and control inflammation. With recent advances in stem
cell therapy, there has been an increased interest in clinical studies evaluating the safety and
efficacy of stem cells. MSCs are considered a favorable option for transplantation due to a
number of factors: ease of isolation, rapid clinical expansion of cultures [78], ability to be
cryopreserved and regenerated without loss of potency [79,80], minimal risk of tumorigenic‐
ity [81,82], multipotent capabilities, and the clinical possibility for autologous transplanta‐
tion [83,84]. Furthermore, MSC transplantation has been tested widely in clinical trials and
considered safe in a variety of neurological, cardiovascular, and immunological diseases [85].
As such, there is great potential for MSCs as a treatment for SCI, which has been well
documented within the literature [53,68,86,87]. There are a number of clinical trials (both
ongoing and completed) to test the potential of using MSCs to treat SCI (for the most current
information, please refer to www.clinicaltrials.gov). Despite promising results of MSC
therapies in animal SCI models and potential for clinical translation, there is yet to be an FDA
approved treatment available for SCI patients.
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Further investigation is needed to fully understand the basic delivery of MSCs and the
mechanistic role in cervical SCI. It has not been established that engraftment and differentia‐
tion of MSCs are even needed for a therapeutic effect, and less than 1% of MSCs survive for
longer than a week when systemically administered [88–90]. This survival rate would be
similar in intraspinal injection. A transplantation study by Paul and colleagues compared the
efficacy of hMSC engraftment when delivered either via lumbar puncture (LP), intravenous
transfer (IV), or direct injection into the injury site in a rat C5 subtotal hemisection model [91].
Based on their results assessing engraftment volume (direct injection > LP > IV), glial scar‐
ring (no difference seen after 21 days of MSC transfer), and host immune response (direct
injection had the highest host immune response), it can be concluded that MSC delivery via
LP is a viable alternative. LP can overcome some of the difficulties of delivering MSCs in
patients at the clinical setting. As a validation, a clinical trial performed by a Japanese group
evaluated the effect of MSCs treatment in a single patient with a C5 fracture dislocation [92].
On day 13, he received an autologous MSC transplant via lumbar puncture and showed
gradual improvement over the 6-month period in both motor and sensory scores graded
according to the American Spinal Injury Association (ASIA) Scoring for International
Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI). Though this is a
single case reported, it appears to be promising for the future of MSCs as an intervention in
cervical SCI.
2.4. Sources of MSCs
2.4.1. From bone marrow stromal cells (BMSCs)
Bone marrow stem/stromal cells (BMSCs) are the most commonly used stem cell source for
transplantation in experimental SCI models. These multipotent cells are derived from the
heterogeneous stroma of bone marrow, which is also comprised of hematopoietic stem cells
(HSC). MSCs are separated from other cells (like HSCs) by the expression of distinctive cell
surface markers [53,67]. Though there has been much speculation about the transdifferentia‐
tion capacity of MSCs into neuronal and glial lineages [71,93], Hofstetter and colleagues
reported that transplanted MSCs could not be induced to differentiate toward a neuronal fate,
either in vitro or in vivo, in spite of the fact the MSCs displayed weak expression of NeuN (a
neuronal marker) [94].
As one of the first identified sources of MSCs, BMSCs have been well studied for their anti-
inflammatory, neurotrophic, and neuroprotective functions in SCI [95,96]. BMSCs transplant‐
ed into the rat spinal cord after a contusion injury demonstrated sensorimotor enhancements,
partly due to their anti-inflammatory effects by attenuating activation of microglia and
astrocytes [97]. To further support their therapeutic role in SCI, BMSC transplantation has been
shown to reduce cavity formation, enhance axonal growth, and also prevent neuronal
apoptosis [86]. While the majority of the studies have explored MSCs potential in a thoracic
injury model, very few studies demonstrate their effect in a cervical SCI model; here we
summarize studies relevant to cervical SCI.
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One of the earliest studies to investigate transplantation within the cervical region investigat‐
ed the use of rat-derived BMSCs in a combinatorial approach with cyclic adenosine mono‐
phosphate (cAMP; a neuronal stimulator) and neurotrophin-3 (NT-3; neurotrophic factor) [98].
Using a dorsal column injury as a model system, cAMP and NT-3 were injected 5 days prior
to a C4 transection at L4 to precondition the DRG soma. BMSCs were then transplanted 7 days
post injury. This combinatorial approach showed successful axon regeneration throughout
and beyond the injury site after 12 weeks that was augmented by preconditioning with cAMP
and NT-3. Despite this, functional recovery was not supported. The authors attribute the
failure to the regenerating axons not reaching their target in the gracile nucleus, a major region
that intercepts sensory information.
MSCs can secrete anti-inflammatory molecules and neurotrophic factors, which can lead to
immunomodulation and tissue regeneration. In addition, they can also be engineered to secrete
factors specific to CNS regeneration. In 2005, Lu and colleagues examined the ability of BMSCs
to promote repair in the injured cord by secreting growth factors that overcome the inhibito‐
ry environment of the lesion [99]. Native or neurally induced rat-derived BMSCs were
modified to either express human brain-derived neurotrophic factor (BDNF) in an acute injury
or NT-3 in a chronic injury model [100]. By 1 month post transplantation within a C3 dorsal
column lesion, BMSC grafts (both native and neurally induced) supported the growth of host
and sensory motor axons, a finding that was augmented by either BDNF or NT-3 transduc‐
tion. Transduction with neurotrophic factors substantially increased the number of coerulo‐
spinal, raphespinal, sensory, and motor axons penetrating the lesion site. Supporting these
results, Novikova and colleagues transplanted BMSCs that were pretreated with Schwann-cell
differentiating factors into a rat C4 hemisection model and demonstrated that BMSCs pre-
stimulated to secrete neurotrophic factors can also contribute to inhibition of astrogliosis and
the post-injury inflammatory response [101].
Another group investigated the combination of BMSCs with rat-derived neural progenitor
cells (NPCs) co-transplanted in a rat C3 dorsal hemisection transection model [102]. As
demyelination is a significant obstacle following SCI, the strategy was employed with the
hypothesis that BMSCs would drive NPCs toward a mature oligodendrocyte lineage. In
contrast with their in vitro data where BMSCs sufficiently redirected NPC differentiation
toward an oligodendrocyte lineage, the group’s in vivo data failed to demonstrate the same 6
weeks post transplant.
Human-derived BMSCs are a clinically attractive transplantation strategy because they can be
reintroduced into patients as autografts or allografts. One preclinical study examined the
transplantation of human-derived BMSCs from the iliac crest of four different healthy donors
into a rat C3–C4 hemisection model [66]. Regardless of donor source, BMSCs survived and
filled the lesion site with minimal migration and substantial axonal growth by 2 weeks post
transplantation. By 11 weeks post transplant, no BMSCs were present within the lesion site,
having been replaced by host oligodendroglial cells. Axonal infiltration into the lesion site and
functional recovery varied by donor; however there was no direct correlation between the
amount of axonal growth and forelimb function. One possible explanation for this is that
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individual donor-based distinctions in the secretory profile of BMSCs contributed to the varied
outcome.
As challenging as the pitfalls within previous results may appear, there are currently two active
clinical trials (Phase I NCT02574572 and Phase II/III NCT0167644) approved by the FDA to
study the safety and efficacy of BMSCs transplanted in patients with chronic SCI. In conjunc‐
tion with human studies, a clinical study tested the dose-dependent efficacy of autologous
human-derived BMSCs in 13 patients with a mix of cervical (five patients) and thoracic
(eight patients) chronic SCI. They found no deleterious effect on the patients; however only
one of the 13 patients showed improvement [103]. It is possible that the absence of statistical
significance can be attributed to the difference in observation of positive outcomes. For
example, while one patient showed an improvement in motor power, two other patients had
a patchy improvement in sensory outcome below the level of injury. At the chronic stage, the
formation of glial scar tissue around the injury lesion is possibly too dense for growing axons
to penetrate. While the transplantation of allogenic BMSCs was deemed safe in patients with
chronic SCI, there is a need for preclinical studies to establish the mechanism of MSC’s
contributory role in chronic SCI.
While spinal cord injury models are in the majority represented by a contusion or hemisec‐
tion injury, damage via herniated discs is also quite a common cause of disability. A herniat‐
ed disc under traumatic events can lead to spinal cord injury. A discectomy is the surgical
removal of the herniated nucleus pulposus of a vertebral disc to reduce pressure on the spinal
cord or radiating nerves. Clinically, a discectomy is treated by fusing artificial prostheses to
replace the intervertebral disc. In a preliminary proof-of-concept study utilizing an ovine
model, one group sought to replicate the intervertebral disc by formulating allogeneic BMSCs
with a chondrogenic agent, pentosan polysulfate, to form a cartilaginous matrix when
implanted into the animal at the C3–C4 and C4–C5 levels [104]. The implant was devoid of
any adverse events, and histological evidence showed predominantly cartilaginous tissue
within the interbody cages. This was further confirmed by CT scans at 3 months post trans‐
plantation that showed significant bone formation in the cohort receiving BMSCs with
pentosan polysulfate when compared to the cohort that received BMSCs alone. Although this
particular study had its limitations, it further illustrates the potential for MSCs in preserving
spinal function and advancing regenerative medicine.
2.4.2. From adipose tissue (AMSCs)
Adipose tissue is equally attractive as a cell therapy source, due to its minimally invasive
harvesting procedure. From a clinical standpoint, adipose-derived stem cells (AMSCs) can
easily be obtained from the large quantities of fat tissue that are removed by routine and safe
procedures such as liposuction and abdominoplasties. Adipose tissue also contains suppor‐
tive stroma that can be isolated and differentiated toward mesodermal lineages [105].
While a vast majority of the literature indicates that AMSCs support axonal growth, a study
utilizing transplanted human-derived AMSCs in a rat C3–C4 hemisection was found to
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significantly reduce sprouting of the descending serotonergic fibers at the injured site [106].
The authors attributed this to several cumulative factors including enhanced survival of
neurons and axons, attenuating the need for excessive sprouting, and reduced astroglial and
microglial reactivity favoring the growth of the fibers into and across the transection site.
Consistent with other MSC transplantation studies, there was no improvement in functional
recovery despite promising microanatomical changes.
Use of AMSCs in humans has been validated for safety and toxicity in both a preclinical testing
and a Phase I clinical trial [82]. It is important that every batch of stem cells prepared for
transplantation into humans is processed under strict GMP conditions and the cultured cells
are verified for absence of toxins and tumorigenic potential in preclinical testing. The pur‐
pose of this study was to evaluate any tumorigenic potential for hAMSCs. Twelve weeks post
transplantation, the safety of transplanted AMSCs showed no significant difference in adverse
events, ECG monitoring, and physical examinations. Though there was no statistical signifi‐
cance in ASIA score, individual patient scores showed improvement at different levels for
motor and/or sensory assessment.
2.4.3. From human umbilical cord blood (UMSCs)
Human umbilical cord blood-derived MSCs (UMSCs) offer various therapeutic advantages in
SCI treatment with reversal of SCI pathophysiology (downregulation of apoptotic genes and
secretion of neurotrophic factors) in as little as 5 days post injury [107]. In an example using a
thoracic SCI, transplantation of UMSCs was reported to have been transdifferentiated toward
neuronal and oligodendroglial phenotypes. This was viewed as being a successful strategy as
evidenced by improved functional motor outcome [86]. These transdifferentiated oligoden‐
drocytes supported the injured spinal cord in remyelination by secreting neurotrophic
factors [108]. UMSCs demonstrate a potential application in the treatment of SCI by their
reported ability to transdifferentiate into neuronal lineages. For further information on UMSCs
in thoracic injury, readers are referred to the review by Park and colleagues [109].
The first clinically based translational study to use UMSCs was in a rat model of radiation
myelopathy, in which significant improvement of the microenvironment previously affected
by radiation therapy was observed [110]. Radiation myelopathy is a rare, yet serious compli‐
cation of cancer radiotherapy. Even though radiation myelopathy is not classified as a
traditional SCI, there are many similarities in pathophysiology such as vascular damage and
demyelination. This particular case study was relevant, as the group studied the efficacy of
UMSCs in a radiation myelopathy model restricted to the cervical spine. Administration of the
UMSCs clearly improved both microvessel and endothelial cell density, along with function‐
al improvement in blood flow. Concurrent with other studies utilizing MSCs, UMSCs were
able to reverse injury induced inflammation by reducing pro-inflammatory and increasing
anti-inflammatory cytokines within the spinal cord. Table 1 shows eight preclinical and clinical
trials involving the transplantation of MSCs, describing study design, injury model, ob‐
served outcomes, and noted adverse effects.
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Study and  
reference (PMID)
Study designs Preclinical
or clinical
trials
Functional
Observations
Histological/
imaging datas
Adverse
events
Long-term results of 
spinal cord injury
therapy using 
mesenchymal stem cells
derived from bone
marrow in humans
(22127044)
Cells: autologous MSCs
harvested from iliac bone
Clinical At 6-month  
follow-up:
- Six out of 10
patients showed
improvement in
motor skills
- Three out of 10
showed gradual
improvement in
daily activities
MRI showed a
decrease in cavity
size and the
appearance of fiber-
like low-signal
intensity streaks
None observed
Dosing: MSCs (8 × 106)
directly injected into
spinal cord and (4 × 107)
were injected into
intradural space
Sample size: N=10
patients with ASIA class
A or B injury caused by
traumatic cervical SCI
After 4 and 8 weeks of
first injection, 5 × 107
injected via lumbar
tapping
Measurements: grading
of motor power, MRI,
electrophysiological
recordings
Intrathecal
transplantation of
autologous  adipose-
derived mesenchymal
stem cells for treating
spinal cord injury:  a
human trial
(26208177)
Cells: autologous
ADMSCs isolated from
lipoaspirates of patient’s
subcutaneous fat tissue
 Clinical At 8-month  
follow-up:
- ASIA motor  
score was
improved in five
patients
- ASIA sensory
score was
improved in 10
patients
- Voluntary and
contraction
improvement
was seen in two
patients
- One patient
showed median
nerve
improvement in
somatosensory
MRI: no significant
interval change for
presence of
tumorous growth
EEG: no significant
change after
transplantation
Urinary tract
infection,
headache,
nausea, and
vomiting were
observed in
three patients
Dosing: 9 × 107 cells per
patient intrathecally
through lumbar tapping
at day 1, 1 month, and
2 months
Sample size: N=14
patients with 12 for ASIA
A, 1 for B, 1 for D
Six patients were injured
at cervical, 1 at
cervicothoracic, 6 at
thoracic, and 1 at lumbar
levels
Measurements: MRI,
hematological
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Study and  
reference (PMID)
Study designs Preclinical
or clinical
trials
Functional
Observations
Histological/
imaging datas
Adverse
events
parameters,
electrophysiology
ASIA motor/sensory
scores were assessed
before and after
transplantation
evoked potential
test
Chronic spinal cord
injury treated with
transplanted autologous
bone marrow-derived
mesenchymal stem cells
tracked by magnetic
resonance imaging: a
case report
(25885347)
Cells: BM-derived MSCs
retrieved from iliac crest
were labeled with
superparamagnetic iron
oxide nanoparticles
Clinical - ASIA B score  
did not change
over 12 months
- At 2 days,
6 months, and
12 months post
operative, both
upper and lower
limbs motor score
had not changes
from
preoperative
levels
- Light touch and
pin prick test also
did not change
MRI: showed
positive signal from
labeled cells in the
cervical region after
48 hours
No change at the
structural level of
injured spinal cord
 at any follow-up
After
transplantation,
patient
experienced
fever, headache,
and myalgia
with increased
neurologic pain
after 12 months
Dosing: intrathecal
transplantation into
lumbar spine with
30 × 106 cells (50:50 ratio
of both labeled and
unlabeled cells)
After transplantation, the
patient was placed in the
Trendelenburg position
for 24 hours
Sample size: N=1 patient
with an incomplete SCI
from the atlantoaxial
subluxation
Transplantation of
autologous bone
marrow mesenchymal
stem cells in the
treatment of complete
and chronic cervical
spinal cord injury
(23948102)
Cells: prepared from BM
collected from iliac spine
Clinical - Ten patients
from treatment
group showed
significant clinical
improvement in
motor, sensory,
and residual
urine volume
- Nine patients
showed changes
in AIS scores
- Eight out of 20
patients in the
treatment group
 N/A One or two
patients in the
treatment group
developed fever
and reported
headaches
Dosing: 8 × 105 cells/μl in
25 μl slowly injected to a
depth of 3 mm at multiple
sites in the central dorsal
area across the junction of
injured and uninjured
spinal cord
Sample size: N=40
patients with complete
and chronic cervical SCI
divided into control and
treatment groups
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Study and  
reference (PMID)
Study designs Preclinical
or clinical
trials
Functional
Observations
Histological/
imaging datas
Adverse
events
showed
significant
improvement in
postoperative
EMG
Localized delivery of
brain-derived
neurotrophic  factor-
expressing
mesenchymal stem cells
enhances functional
recovery following
cervical spinal cord
injury
(25093762)
Cells: WT-MSCs or  
BDNF-MSCs
MSCs derived from BM
 of adult transgenic rats
expressing GFP and
transduced with murine
leukemia virus encoding
BDNF
MSCs characterized by
cell surface expression of
CD105 and lack of CD45
Preclinical:
unilateral
spinal cord
hemisection
at C2 in
Sprague-
Dawley rats;
male
 N/A Retrograde labeling
with CTB showed
localization of
MSCs near injection
site and primarily
in the white matter
At day 14 after
transplantation, all
rats treated with
BDNF-MSCs
showed functional
recovery of
diaphragm
 N/A
Dosing: 2 × 105 cells
injected intraspinally at
C2 at time of injury
Measurements:
immunohistochemistry,
electromyogram (EMG)
Bone  morphogenetic
proteins prevent bone
marrow stromal cell-
mediated
oligodendroglial
differentiation of
transplanted adult
neural progenitor cells
in the injured spinal
cord
(23770801)
Cells: NPC isolated from
sub-ventricular zone and
BMSC isolated from bone
marrow
Preclinical:
C3 complete
transection
in adult
female
Fischer 344
rats
None In vitro assays
demonstrate
blocking of BMP
signaling enables
BMSC-induced
differentiation of
NPCs to
oligodendrocytes
Dosing: immediately
following the transection,
cell suspensions (2 μl)
containing either only
BMSCs (0.6 × 105
BMSCs/μl; N=5), only
NPCs (1.8 × 105 NPCs/μl;
N=5), or a mixture of
NPCs and BMSCs
(1.2 × 105 NPCs/μl mixed
with 0.3 × 105 BMSCs/μl;
N =6) were administered
by a single injection into
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Study and  
reference (PMID)
Study designs Preclinical
or clinical
trials
Functional
Observations
Histological/
imaging datas
Adverse
events
the center of the lesion
site
Neuroprotective and
growth-promoting
effects  of bone
marrow stromal cells
after cervical spinal  
cord injury in  adult
rats
(21521004)
Cells: harvested from
femur  and tibia of rats
and differentiated to a
Schwann-cell phenotype
Preclinical:
C4
hemisection
in Sprague-
Dawley rats;
female
 N/A At 6–8 weeks: NF-
positive fibers,
serotonin-positive
raphespinal axons
and CGRP sensory
axons were seen in
the injured cord
 N/A
Dosing: 10–12 × 106 cells
were injected into lateral
funiculus at approx.
1 mm from the rostral
and caudal site to the
lesion
Measurements:
immunohistochemistry
Grafting of human bone
marrow stromal cells
into spinal cord injury:
 a comparison of
delivery methods
(19182705)
Cells: frozen hMSC
thawed and transplanted
Preclinical:
right
subtotal
hemisection
at C4–C5
Sprague-
Dawley rats;
female
 N/A Cells delivered via
LP showed:
- Early tissue
sparing in
immunostaining for
GFAP
- Reduced host
immune response
staining for ED1
(macrophage) and
CD5 (pan T-cell
marker)
 N/A
Dosing: animal groups
received either 1 × 106  
cells transplanted via LP
or IV or 1.5 × 105 cells
directly  at injury site
Measurements: histology,
immunohistochemistry
Table 1. Tabulated summary of preclinical and clinical trials involving the transplantation of MSCs; for each trial the
study design, injury model, observed outcomes and adverse effects are described.
3. Embryonic-derived stem cells (ESCs)
3.1. Derivation of embryonic stem cells
Embryonic stem cells (ESCs) represent an intriguing avenue to pursue in the race to under‐
stand and treat neurodegenerative pathophysiology. Their pluripotency makes them an
extremely versatile option when compared to the limitations of MSCs, and the basic cell culture
techniques governing them have been established for decades. ESCs are pluripotent cells
derived from the inner cell mass harvested at the embryonic blastocyst stage. Unlike multi‐
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potent stem cells, such as MSCs, that are limited to mesoderm lineages, ESCs have the ability
to give rise to all three germ layer lineages: the ectoderm, endoderm, and mesoderm. The
capacity to generate neuronal lineages under directed conditioning makes them an ideal target
for cell-based therapies of the nervous system [111–113]. Furthermore, ESCs possess the ability
to self-renew, a key characteristic of stem cells that allows for a potentially indefinite source
of cells.
ESCs were first harvested and cultured in the early 1980s from murine sources and eventual‐
ly followed by human sources in the late 1990s [113–116]. Key differences in the in vitro
culturing of these cells were responsible for the almost 20-year gap between the successful
harvesting of murine versus human-derived ESCs. Murine ESCs are capable of surviving
without the support of fibroblast feeder layers but require the addition of leukemia inhibito‐
ry factor (LIF). This led to earlier xeno-free expansion and characterization than human
sources, which were later found to rely on the addition of fibroblast growth factor (FGF) to
retain their pluripotency and stem cell characteristics [117].
Despite the positive attributes of ESCs, there are certain shortcomings that cannot be over‐
looked. Current research utilizing human-derived ESCs is still limited by the lack of chemi‐
cally defined, in vitro culture conditions and is often dependent on the extracellular matrix and
growth factor support of Matrigel substrates [118–120]. Additionally, the harvesting and
culture of human-derived ESCs raise ethical concerns and extended culturing has been debated
to lead to karyotypic stability. In vivo use of ESCs often leads to teratoma formation and the
need for immunosuppressant drugs, all of which pose a problem for usage in clinical studies
[111,121–123]. Current research strategies have centered around developing high-efficiency,
high-purity differentiation protocols in order to generate committed or progenitor cell
populations that limit their teratogenicity and enhance their therapeutic potential.
3.2. The regenerative potential of ESCs
In treating SCI, groups have looked to generate neural and glial-specific lineages such as
oligodendrocytes, astrocytes, and neurons from ESCs. The majority of differentiation proto‐
cols lead to high astrocyte and oligodendrocyte populations and relatively few neurons, likely
due to the proliferative capacity of the supporting glial cell types compared to neurons
[40,111,124–126]. Differentiation methods developed by the McDonald and Keirstead groups
have extensively researched the high-efficiency generation of oligodendrocyte progenitor
cells (OPCs), which have proven useful in improving myelination and functional outcomes of
increased weight support and partial hindlimb gait coordination after thoracic SCI [40,127–
131].
Elegantly designed directed differentiation protocols from the Jessell research group using
retinoic acid and sonic hedgehog have led to generation of spinal motor neurons from ESCs,
which expressed progenitor motor neuron (pMN) marker Olig2 followed by classic motor
neuron markers, Isl1, Hb9, and choline acetyltransferase (ChAT) [132]. When grafted into
embryonic day 27 chick spinal cords, these cells have shown integration into the ventral spinal
cord and acquire appropriate native motor pool identities [132,133], indicating a potential cell
source for lost motor neuron pools after SCI. The Keirstead group has also investigated the
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spontaneous differentiation of human ESC-derived neural progenitor cells (NPCs) into various
neuronal phenotypes such as cholinergic, serotonergic, dopaminergic (DA) and/or noradre‐
nergic, and medium spiny striatal neurons [130,134]. Unfortunately, when ES-derived NPCs
are transplanted as a heterogenic population, over-proliferation of undifferentiated stem cells
can occur and potentially lead to tumor formation [135]. Further research has investigated the
ways to mitigate this over-proliferation through antibiotic selection in order to generate high-
purity progenitor motor neurons and committed motor neuron populations [136–138].
The first study to demonstrate that stem cells could be induced toward a cortical projection
lineage utilized murine ES cells [139]. Appropriate culture conditions and in vitro patterning
led to the generation of neural precursor cells that initially express forebrain progenitor-
specific genes and later features of cortical pyramidal neurons. Most interestingly, transplan‐
tation of these cultures into various locations in the mouse brain led to area-specific axonal
and dendritic growth, connectivity and integration within the host CNS, and axon extension
to developmentally appropriate targets. These results suggest that it is possible to drive stem
cells toward committed neural subtypes that can integrate into anatomically relevant cir‐
cuits in vivo.
With all of these various cell populations, numerous cell-based treatment strategies for SCI
have been investigated; however the overwhelming majority of these studies have been
completed in thoracic injury models. Despite cervical injuries comprising more than 50% of
the SCI population, very little preclinical research has been completed to date in this repre‐
sentative model [111].
3.3. Treating cervical SCI with ESCs
The first study to use embryonic-derived stem cells for therapy in a cervical SCI model was
from Sharp and colleagues, looking at the use of human ESC-derived OPCs in a severe midline
contusion cervical SCI rat model [140]. The hESC-derived OPCs used in this study were
derived using the same protocol [130,131,141,142] as those used in earlier thoracic injury
models from the Keirstead group [39,142] and in the Geron™-sponsored, clinical trial (first to
use human ESCs as a therapeutic) that was halted in 2011 due to financial and safety con‐
cerns [143,144]. This study found that transplanting hESC-derived OPCs 7 days post injury
led to a decrease in lesion area accompanied by robust white and gray matter sparing 8 weeks
post transplant. Transplanted cells remained localized within the lesion epicenter with
minimal rostral or caudal migration. Notably, the preservation of endogenous motor neu‐
rons was correlated with increased forelimb function. Finally, the use of transplanted hESC-
derived OPCs led to differential changes in spinal cord gene expression for neurons, growth
factors, apoptosis, and inflammation [140]. As such, injured animals with transplanted cells
saw gene expression levels more closely matching their uninjured counterparts when
compared to transplant-naïve animals. Since the discontinuation of the Geron™-sponsored
thoracic injury clinical trial, Asterias Biotherapeutics, Inc., has undertaken the use of hESC
AST-OPC1 cells for clinical use in a new Phase I/IIa efficacy and safety trial for cervical-level
injuries (NCT02302157).
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While most of the literature utilizes acute injury models to study the intervention of stem cells,
one group investigated the use of hESC-derived OPCs in a rat cervical chronic injury model.
In the 2013 study by Sun and colleagues, Olig2+ GFP+ OPCs derived from mouse ESCs were
transplanted 4 months post rat cervical irradiation injury [145]. The irradiation injury model
is a chronic injury commonly caused by radiotherapy for cancer treatment that results in the
death of oligodendrocytes, which leads to severe demyelination and increased axon death.
By 8 weeks post transplant, there was significantly less demyelination in addition to im‐
proved forelimb locomotor function using a clinical degree of weakness scale. Transplanted
hESC-OPCs differentiated primarily into mature oligodendrocytes that expressed myelin basic
protein. These cells were produced using a retinoic acid/sonic hedgehog differentiation
protocol similar to the ones developed by the Jessell and Zhang groups [132,146].
The Keirstead group has also exploited the potential for ESCs to differentiate into neural
lineages for use in cervical SCI treatments. They demonstrated successful use of hESC-derived
progenitor motor neurons (pMNs) in a cervical SCI contusion model. The pMNs were
generated using a retinoic acid differentiation protocol over 28 days and were shown to be
Olig1/2+, as well as Tuj1 and Hb9 positive. Electrophysiology of these cells indicated gluta‐
mate receptors after 8 weeks in culture and could innervate both human and rodent muscle
tissues. In vivo, reduced SCI pathology, or lesion size, and greater endogenous neuron survival
and growth were observed in hESC-pMN transplanted spinal cords. Furthermore, these
outcomes correlated with increased functional recovery on the balance beam task [147]. The
authors did note, however, that differentiation of transplanted cells was dependent on location.
Cells that were found in the distal ventral horn led to increased differentiation, whereas cells
confined to the site of injury reverted to a progenitor state.
Other embryonic or fetal-derived tissues have been used in spinal cord injury therapies,
including whole fetal spinal cord transplants (pioneered by Reier and Anderson) and fetal
neural progenitor/stem cells taken from brain and spinal tissue [51,111,123,148–157]. In the
study by Diener and Bregman, transplantation of fetal spinal cord tissues into cervical
hemisections led to supraspinal growth, axon projections, improved skilled forelimb func‐
tion indicating transplanted cell survival, and potential local circuit formation. Further
investigation of fetal spinal cord lineage-restricted NPCs by various groups has indicated
differentiation of transplanted cells into all three neural lineages, in both cervical and thoracic
level injuries, with long distance cell migration and axon growth leading to functional
improvement [123,148–151,158]. Two clinical trials have begun since 2013 investigating the
use of fetal-derived tissues for spinal cord injury [144]. StemCells, Inc.® have begun a safety
and efficacy study using human-derived CNS-stem cells (proprietary source) in cervical SCI
after completing a thoracic injury trial [159]. Neuralstem, Inc., is also investigating the use of
fetal stem cells in SCI [160,161] after promising results using such cells in ALS treatment. This
trial, however, is determining the efficacy of these cells in a thoracic injury model. While these
cells have proven useful in improving functional outcomes after SCI in preclinical trials, they
are subject to the same ethical concerns as those for ESCs and have limited differentiation
capacity in comparison [162].
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In treating SCI, ESCs demonstrate great potential in promoting axon regeneration and
functional recovery, but the lack of full characterization of cell safety, efficacy, and pheno‐
type has significantly limited their clinical applications. Furthermore, the use of ESCs in
cervical SCI models is limited to less than a handful of peer-reviewed studies. As cervical
injuries are becoming more prevalent, future studies must be designed that better replicate
clinical injuries in order to more accurately test cell therapeutic strategies.
4. Induced pluripotent stem cells (iPSCs)
4.1. Derivation of iPSCs
Induced pluripotent stem cells (iPSCs) are created by reprogramming adult somatic fibro‐
blasts to revert to a pluripotent stem cell state initially via retroviral delivery of Oct3/4, Sox2,
c-Myc, and Klf4 [163–165]. Now iPSCs can be generated via multiple processes, each with its
own merits and limitations. Viral transduction is easy to use and reproducible, yields iPSCs
efficiently, and is controlled. However there is an increased risk of insertional mutagenesis
and transgene reactivation, incomplete splicing, and clone-to-clone variation [166–168].
Reprogramming factors can also be fused to cell-penetrating peptides or introduced through
plasmids, which requires no genomic modification but is also a time consuming and poten‐
tially inefficient process [169]. Finally iPSCs can be induced via mRNA introduction, which is
a highly effective and rapid method; it also requires no genomic modification and is deemed
safe due to the transient nature of mRNA. However, repeated transfections are typically
required [170,171].
While MSCs are hindered by their limited potency and the harvesting of ESCs is subject to
ethical constraints, the pluripotency and source of iPSCs circumvent some of these issues,
therefore making them a promising alternative in cellular transplantation therapies. iPSCs
share many similarities with ESCs and provide a comparative alternative in that they have the
same morphology, gene markers, and potential to form teratomas (ability to differentiate into
all three germ layers) [163,165]. Furthermore, the use of iPSCs opens up new possibilities for
clinical consideration—ethical concerns are diminished and, in the case of potential trans‐
plants, cells can be harvested directly from the patient, therefore avoiding the need for
immunosuppression.
4.2. Cell reprogramming technologies for controlled differentiation
There has been a strong motivation to create iPSC differentiation protocols that drive stem
cells toward the three main neural lineages in vitro. Methods to generate functional neurons
have been of particular interest so as to study the differences in neuronal networks in both
healthy and impaired states [172–177]. In one report, mature human fibroblasts were direct‐
ly programmed into synaptically active functional neurons via a cocktail of miR-124, BRN2,
and MYT1L [178]. An additional group found that Ascl1 (which has pioneer factor proper‐
ties) in conjunction with BRN2, and MYT1L, successfully drove murine fibroblasts into
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neuronal cells with appropriate morphology, expression, and formation of functional
synapses [179]. One report demonstrated that the overexpression of neurogenin 2 efficiently
transformed iPSCs into functional neurons that were able to spontaneously form excitatory
synaptic networks. Furthermore, these networks both synaptically integrate once transplant‐
ed into the mouse brain and exhibit plasticity [180]. The majority of research utilizes iPSCs
driven toward a neural progenitor state [181,182]; however iPSC differentiation has also been
useful in disease modeling. As an example, midbrain dopaminergic (DA) neuron pheno‐
types have been generated, which has been particularly useful in studying Parkinson’s
disease (PD), typically characterized by the loss of these DA neurons [183–186]. In one study
by the Pera group, a stable iPSC line was derived from a PD patient that carried the most
common PD-associated genetic mutation and differentiated into midbrain DA neurons. These
iPSC-derived DA neurons exhibited classic hallmarks of PD-related damage including
accumulation of α-synuclein and oxidative stress, susceptibility to H2O2-induced CASP3
activation, and sensitivity to 6-OHDA and proteasome inhibition. Additionally, other groups
have shown that iPSCs can be successfully driven toward glutamatergic, GABAergic, motor,
and retinal neuron phenotypes [187–199]. While not specific to SCI, these results demon‐
strate that developing differentiation protocols capable of generating specific neural sub‐
types can open up new research avenues in understanding and creating therapies for
neuropathologies.
There is also interest in reliably driving iPSCs toward functional glial subtypes, as glial cells
are heavily affected in the process of neurodegeneration. In a study by Krencik and Zhang,
exogenous patterning molecules were used to transform iPSCs into a neuroepithelial pheno‐
type. From there, administration of mitogens allowed for the generation of astroglial progen‐
itors, which could then be further differentiated into functional astrocytes via ciliary
neurotrophic factor [200]. Another protocol utilized the forced expression of Sox10, Olig2, and
Zfb536 to directly reprogram rodent fibroblasts into oligodendrocyte precursor cells. The
resulting population of precursors exhibited typical morphology and gene expression and
gave rise to mature oligodendrocytes that could ensheath dorsal root ganglion cells in vitro
and form myelin in vivo [201].
The intended goal behind SCI therapies is to ameliorate damage and restore the circuitry
within the CNS. Cellular transplantation offers an innovative means in accomplishing this, but
is obviously extremely dependent upon the characteristics and capabilities of the transplant‐
ed cell type. Driving human iPSCs toward neuronal lineages via reproducible and robust
differentiation protocols represents a practical interface between developmental neurobiolo‐
gy and SCI research; it may be possible to tailor iPSCs toward a more developmentally
appropriate, specific neuronal cell type capable of restoring CNS connectivity rather than the
uncharacterized progenitor populations previously used with limited functional recovery.
4.3. Treating cervical SCI with iPSCs
Similar to MSC and ESC-focused SCI therapies, there is a scarcity of targeted preclinical
therapies for SCI using iPSC transplantation. Therapies do show positive outcomes yet they
are limited in number; to date there are only five published studies using either rodent or
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simian models of thoracic SCI [202]. In these studies, iPSCs were driven toward neural stem
spheres [203], neural stem cells (NSCs) [202,204], and neurospheres [205,206] with all except
one study experiencing amelioration of the inhibitory nature of the lesion site, synaptic
integration of transplanted cells, and significant functional improvement in transplanted
animals.
Therapies targeting cervical SCI are equally as limited. There are four published studies to
date that have examined acute, subacute, and chronic iPSC transplantation following cervical
SCI. Li and colleagues evaluated respiratory function following transplantation of iPSC-
derived astrocytes engineered to overexpress GLT1, an astroglial glutamate transporter [207].
Both rats and mice underwent a C4 contusion injury resulting in chronic diaphragm dysfunc‐
tion and phrenic motor neuron deterioration. Immediately post injury, subjects received two
separate intraspinal injections rostral and caudal to the lesion within the ventral horn. At time
points ranging from 2 days to 4 weeks post transplant, it was demonstrated that transplant‐
ed grafts survived and differentiated into GFAP-positive astrocytes, were not tumorigenic,
and had less than 10% proliferation (evidenced by Ki67 staining). Furthermore, lesion area and
volume were reduced within 1 mm rostral and caudal to the lesion epicenter and innerva‐
tion of the diaphragm neuromuscular junction was preserved in animals that had received
iPSC-derived astrocyte transplants that overexpressed GLT1. Through analysis of spontane‐
ous electromyogram (EMG) activity, GLT1-overexpressing astrocyte transplants significant‐
ly magnified EMG amplitude in the dorsal region of the hemidiaphragm, further
demonstrating preservation of diaphragmatic respiratory function.
Another study by Lu and colleagues examined the effect of human iPSC-derived NSCs
harvested from an elderly donor in a C5 lateral hemisection rat model [208]. While the chosen
cell population was minimally characterized, in vitro analysis demonstrated reduced expres‐
sion of Tra1-81 and SSEA4 (pluripotency markers) and maintained expression of nestin and
Sox2 (NSC-associated markers). Two weeks post injury, NSCs were intraspinally co-trans‐
planted with a fibrin matrix and a raft of growth factors. By 3 months post transplantation,
there was evidence that the grafted cells had survived, distributed throughout the lesion, and
integrated with host axons. The majority of grafted cells expressed NeuN and mature neuronal
markers MAP2 and Tuj1 alongside mature astrocytic marker GFAP, suggesting preferential
differentiation into neuronal and astrocytic lineages. There was also evidence of prolifera‐
tion and spinal motor neuron identity within a small percentage of transplanted cells via the
expression of Ki67 and ChAT, respectively. Most notably, a remarkable amount of axonal
growth was present extending from the lesion site toward the olfactory bulbs and lumbar spine
sections. Despite robust axonal growth, no behavioral recovery was observed.
In consideration of the substantial lack of existing chronic cervical SCI data, Nutt and
colleagues investigated an early chronic injury model mimicking the deficits seen in human
injury [209]. Four weeks following a cervical contusion injury at C4, iPSC-derived neural
progenitor cells and fibroblasts were co-transplanted rostral and caudal to the lesion in a rat
model. Immunohistochemical analysis suggested the differentiation of transplanted cells into
mature neurons as well as the intermingling of the host CNS with transplanted cells, as
evidenced by NeuN/FOX-3 labeling. Despite interactions between host and donor cells,
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transplanted cells did not express glutamate receptors. Furthermore, transplanted cells were
not positive for serotonin but did express GABA and were shown co-localized with host
positive choline acetyltransferase. Behavioral recovery was weak; grasping and weight bearing
were only slightly improved by transplants.
MSCs ESCs iPSCs
Source Bone marrow, adipose,
umbilical cord
Fetal tissue Somatic (adult) cells
Lineage differentiation Mesodermal lineage All three germ layers—
endoderm, mesoderm, and
ectoderm
All three germ layers—
endoderm, mesoderm, and
ectoderm
Derivation Purified by surface markers
from adult tissue
Embryonic (inner cell mass of
blastocyst)
Induced or reprogrammed to
“stemness”
Ease of isolation Easily accessible sources Difficult; isolated from fetal
tissue
Easily accessible sources (e.g.,
skin)
Differentiation potential Multipotent Pluripotent Pluripotent
Ethical issues Minimal; cells can be
isolated from the patient
Strong concerns Minimal; even skin cells can be
induced to be pluripotent
Axonal regrowth Yes; by tissue sparing and
neuroprotection
Yes; by transdifferentiation Yes; by transdifferentiation
Functional outcome Mild to moderate Moderate Mild to moderate
Immunomodulatory Yes Low Low
Immunogenicity/
autologous
Low; safe for autologous
transplantation
High; often requires
immunosuppression
Low; safe for autologous
transplantation
Tumorigenicity No tumor formation Teratoma formation Teratoma formation
Clinical trial Advanced to Phase III Advanced to Phase II Preclinical only
Table 2. A comparative scheme of the characteristics of MSCs, ESCs and iPSCs described in this chapter.
In contrast, Kobayashi and colleagues examined the safety and efficacy of iPSC-derived NSC
transplants in a simian model of cervical SCI [210]. Human iPSCs were cultured and in‐
duced to form neurospheres and passaged a secondary and tertiary time prior to transplan‐
tation. Adult female marmosets were given a moderate contusion at the C5 level and received
an intraspinal injection of cultured iPSC-neurospheres 9 days post injury at the lesion site.
By 12 weeks post transplant, hematoxylin-eosin staining revealed that the grafted cells
survived and were positive for NeuN, GFAP, and Olig 1 indicating differentiation into all three
neural subtypes. Additionally, animals that received transplants had reduced cystic cavity
size, no evidence of tumorigenicity, increased angiogenesis, and a higher amount of neurofi‐
laments and descending motor axons at the lesion center. Severe demyelination was evident
surrounding the lesion site in both transplanted and control groups; however, the amount was
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significantly exacerbated in animals that did not receive cellular transplantation. These
findings were further supported by MRI and myelin mapping in which myelin sparing was
more evident in the transplanted group and an intramedullary high-signal intensity area in
the lesion site of the control group. Calcitonin-generated peptide fibers, which are involved in
spinal pain mechanisms, did not differ between transplanted and control groups. In nonhu‐
man primates, contusion at the C5 level in a severed central cord injury model leads to
tetraplegia with an expected gradual improvement in motor function. By 8 weeks post injury,
there were significant differences in the open field test, bar grip strength test, and cage climbing
tests between transplanted and control groups, which stayed consistent throughout the study
indicating some level of functional recovery due to transplantation. Promising results from
the various cell-based therapies have demonstrated varying degrees of axonal regeneration
and functional recovery. Table 2 provides a summary of the characteristics of MSC, ESC, and
iPSC types and also notes their functional outcomes, tumorigenicity, and clinical trial stage to
date.
5. Summary and conclusions
Great care and consideration must be taken when choosing an optimal stem cell type as a
potential cellular transplantation treatment for cervical SCIs. Of the three main stem cell types
discussed here, there are distinct advantages and disadvantages to each. The use of MSCs in
treating nervous system injuries remains a hotly debated topic due to their limited survival,
differentiation potential, and functional recovery outcomes. Nevertheless, their immunomo‐
dulatory properties and growth factor secretion make them potentially beneficial for use in
combinatorial strategies especially if delivered noninvasively. ESCs offer significantly more
differentiation potential for neural applications than adult stem cells and have the added
benefit of promoting functional recovery in cervical SCI models. However, the lack of detailed
cell characterization, need for immunosuppression, and overall ethical concerns have led to
only a single cervical SCI clinical trial. Moreover, the use of ESCs in preclinical cervical SCI
studies is limited to only two ESC-derived phenotypes (OPCs and pMNs). Significant research
must still be performed to fully explore alternative appropriate cell types that can potential‐
ly promote functional regeneration. Finally iPSCs, the newest technology in stem cell sour‐
ces, propose an interesting alternative to fate-limited MSCs and ethically restricted ESCs in
treating cervical SCI. Promising preclinical data has indicated iPSC-based therapies can
improve functional outcomes after injury; however, their recent discovery highlights the need
for careful characterization and exploration of secure differentiation protocols. Further studies
must still be completed before iPSCs can be approved for clinical applications.
While stem cell transplantation therapies have shown promise in promoting post-injury
regeneration, both anatomical and functional recovery still remain imperfect; no preclinical or
clinical study to date has dramatically restored significant recovery in patients. Experimen‐
tal evidence has shown that native regeneration and plasticity occur in limited amounts
following injury. These innate processes can be enhanced via the addition of neurotrophic and
immunomodulatory factors, the removal of lesion-associated inhibitory factors, and injury-
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appropriate rehabilitation regimens and physical activity. It would be of great interest to
determine whether combinatorial approaches utilizing stem cell transplantation in conjunc‐
tion with the strategies described above provides a synergistic effect within the living system.
Furthermore, the vast majority of cell transplantation studies utilize cell populations driven
toward immature final phenotypes. The pluripotent capabilities of ESCs and iPSCs provide
the freedom to drive these cell types toward numerous definitive lineages or ages. This,
however, will be defined by developing appropriate differentiation protocols that can be used
in both preclinical and clinical settings. It is possible that transplanting more mature cells
results in the establishment and integration of meaningful circuitry within the host nervous
system to restore and promote functional recovery.
The broad scope of stem cell therapies offers a myriad of therapeutic potential. However, due
to the limited number of preclinical and clinical studies, extensive logistical questions remain
regarding how to optimize their usage. Nonetheless, the great strides made in designing and
improving effective stem cell therapies for enhancing function promises an exciting future for
the field of spinal cord injury repair.
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